EPS for Adamas Pharmaceuticals, Inc. (ADMS) Expected At $-1.44

July 14, 2018 - By Frank Plummer

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Logo

Analysts expect Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) to report $-1.44 EPS on August, 14.They anticipate $0.51 EPS change or 54.84 % from last quarter’s $-0.93 EPS. After having $-1.35 EPS previously, Adamas Pharmaceuticals, Inc.’s analysts see 6.67 % EPS growth. The stock increased 2.73% or $0.72 during the last trading session, reaching $27.06. About 491,901 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has risen 88.75% since July 14, 2017 and is uptrending. It has outperformed by 76.18% the S&P500.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Coverage

Among 6 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamas Pharmaceuticals had 11 analyst reports since January 23, 2018 according to SRatingsIntel. As per Wednesday, April 4, the company rating was initiated by Leerink Swann. The stock has “Buy” rating by Mizuho on Thursday, April 19. The rating was maintained by Mizuho on Tuesday, February 20 with “Buy”. The firm has “Buy” rating by Piper Jaffray given on Thursday, February 22. Mizuho maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) on Friday, March 9 with “Buy” rating. Needham maintained it with “Buy” rating and $40.0 target in Friday, February 23 report. Evercore maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) rating on Tuesday, February 20. Evercore has “Buy” rating and $85.0 target. The firm earned “Buy” rating on Friday, June 22 by Mizuho. The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has “Buy” rating given on Tuesday, January 23 by Mizuho. The firm earned “Buy” rating on Tuesday, January 30 by Piper Jaffray.

Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders. The company has market cap of $730.14 million. The company's product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It currently has negative earnings. The Company’s portfolio also comprises of Namzaric capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

More news for Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) were recently published by: Globenewswire.com, which released: “Adamas Announces New Employment Inducement Grant” on July 09, 2018. Nasdaq.com‘s article titled: “Adamas Presents New Data Analysis Demonstrating that GOCOVRIâ„¢ Reduces Transitions between Dyskinesia and …” and published on June 22, 2018 is yet another important article.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.